Skip to content

Treatment of Rheumatoid Arthiritis with Unani formulations

Validation of a Unani Pharmacopoeial formulation in Waja ul Mafasil (Rheumatoid Arthritis)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/12/004199
Enrollment
300
Registered
2013-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement Health Condition 2: null- Waja ul Mafasil (Rheumatoid Arthritis)

Interventions

Intervention1: 1. Majoon-e-Suranjan 2.Safoof suranjan 3.Raughan e Suranjan: 1.Majoon-e-Suranjan 7 gm orally two times daily with water. 2.Safoof suranjan 6gm two times daily with water. 3. Raughan e

Sponsors

Monetary Support Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex in the age group of 20-60 • Patients fulfilling the ACR criteria for rheumatoid arthritis i.e the 2010 American College of Rheumatology/European League Against Rheumatism classification Criteria for rheumatoid arthritis

Exclusion criteria

Exclusion criteria: • Patients having Gout, or complicated rheumatoid arthritis associated with deformity. • Abnormality in any investigation done at baseline (SGOT, SGPT and ALP,Sr Creatinine, B.Urea would be considered abnormal if raised 2 ½ times the normal value ) • Overweight subjects â?? BMI 35 • Disorders requiring long term treatment • Drug addicts ( Alcohol, drugs ) • Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptomsTimepoint: 12 weeks

Secondary

MeasureTime frame
Hematological and biochemical assessments for safetyTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Abdul Hannan

Central Council for Research in Unani Medicine (CCRUM)

ccrum605@gmail.com011-28521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026